Emmaus Life Sciences Inc (EMMA)
0.10
-0.01
(-5.88%)
USD |
OTCM |
May 17, 15:50
Emmaus Life Sciences Enterprise Value: 36.63M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 36.63M |
| May 15, 2024 | 36.45M |
| May 14, 2024 | 36.45M |
| May 13, 2024 | 36.56M |
| May 10, 2024 | 36.56M |
| May 09, 2024 | 36.56M |
| May 08, 2024 | 36.29M |
| May 07, 2024 | 36.83M |
| May 06, 2024 | 36.83M |
| May 03, 2024 | 36.29M |
| May 02, 2024 | 36.38M |
| May 01, 2024 | 36.29M |
| April 30, 2024 | 36.29M |
| April 29, 2024 | 36.29M |
| April 26, 2024 | 36.29M |
| April 25, 2024 | 36.29M |
| April 24, 2024 | 36.29M |
| April 23, 2024 | 35.87M |
| April 22, 2024 | 35.87M |
| April 19, 2024 | 35.87M |
| April 18, 2024 | 37.03M |
| April 17, 2024 | 37.03M |
| April 16, 2024 | 37.03M |
| April 15, 2024 | 36.56M |
| April 12, 2024 | 36.56M |
| Date | Value |
|---|---|
| April 11, 2024 | 36.56M |
| April 10, 2024 | 36.56M |
| April 09, 2024 | 36.56M |
| April 08, 2024 | 36.56M |
| April 05, 2024 | 36.90M |
| April 04, 2024 | 36.56M |
| April 03, 2024 | 36.56M |
| April 02, 2024 | 36.56M |
| April 01, 2024 | 37.03M |
| March 28, 2024 | 36.56M |
| March 27, 2024 | 37.21M |
| March 26, 2024 | 35.76M |
| March 25, 2024 | 35.76M |
| March 22, 2024 | 36.45M |
| March 21, 2024 | 37.80M |
| March 20, 2024 | 35.76M |
| March 19, 2024 | 35.52M |
| March 18, 2024 | 36.35M |
| March 15, 2024 | 36.35M |
| March 14, 2024 | 37.10M |
| March 13, 2024 | 37.10M |
| March 12, 2024 | 36.92M |
| March 11, 2024 | 36.84M |
| March 08, 2024 | 36.76M |
| March 07, 2024 | 36.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.014M
Minimum
May 22 2019
461.22M
Maximum
Jul 18 2019
65.91M
Average
51.98M
Median
Nov 11 2020
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.080M |
| Perspective Therapeutics Inc | 890.47M |
| Protalix BioTherapeutics Inc | 57.71M |
| Electromed Inc | 135.95M |
| Armata Pharmaceuticals Inc | 189.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.067M |
| Revenue (Quarterly) | 5.018M |
| Total Expenses (Quarterly) | 4.994M |
| EPS Diluted (Quarterly) | 0.0005 |
| Gross Profit Margin (Quarterly) | 95.74% |
| Profit Margin (Quarterly) | 1.34% |
| Earnings Yield | -89.52% |
| Operating Earnings Yield | 10.52% |
| Normalized Earnings Yield | -104.30 |